The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Insights into a study validating the ICC hierarchical classification in secondary AML
Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, shares insights from a study validating the International Consensus Classification (ICC) in secondary acute myeloid leukemia (AML). Dr Voso highlights that the genetic background, including cytogenetics and myelodysplasia-related mutations, is the major determinant of patient prognosis and identifies two distinct subgroups of myelodysplastic syndromes (MDS)-AML with different mutation patterns, confirming that stratification and treatment should follow genetics rather than prior patient history. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
